The Mesothelioma Applied Research Foundation (Meso Foundation) awarded a research grant to detect gene mutations in specific subtypes of peritoneal mesothelioma in hopes of identifying already available therapies for these patients as well as developing new screening tools.
The study, led by Waqas Amin, M.D., with the University of Pittsburgh, will analyze three histological subtypes (epithelioid, biphasic and sarcomatoid) in peritoneal mesothelioma to find the most significant gene mutations for better characterization and identification of genetic variants.
Mesothelioma is a rare form of cancer associated with asbestos exposure. Peritoneal mesothelioma is the second most common type of the disease, affecting the lining that surrounds the abdomen. (Pleural mesothelioma is the most common form of mesothelioma and affects the lining surrounding the lungs.)
There is currently no one single standard of treatment for peritoneal mesothelioma, though some experts specializing in this rare form of the disease have seen success with HIPEC (hyperthermic intraperitoneal chemotherapy). But, questions remain as to why certain treatments work on some patients but not with others.
Dr. Amin hopes that by detecting these gene mutations, he can better identify which currently available therapies would be more beneficial for peritoneal mesothelioma patients.
The Meso Foundation’s peer-reviewed grant program funds promising and impactful mesothelioma research. The grants are funded in their entirety by families affected by mesothelioma through personal donations and through fundraising events in their communities. To date, the Meso Foundation has awarded more than $10.2 million for cutting-edge mesothelioma research.
Source: Meso Foundation